Chapter 1. Research Scope

1.1. Research Objectives

1.2. Market Definition

1.3. Analysis Period

1.4. Market Size Breakdown by Segments

1.4.1. Market size breakdown, by phase

1.4.2. Market size breakdown, by therapeutic application

1.4.3. Market size breakdown, by service

1.4.4. Market size breakdown, by end user

1.4.5. Market size breakdown, by region

1.4.6. Market size breakdown, by country

1.5. Market Data Reporting Unit

1.5.1. Volume

1.5.2. Value

1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.1.1. Paid

2.1.2. Unpaid

2.1.3. P&S Intelligence database

2.2. Primary Research

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics

5.1.1. Trends

5.1.2. Drivers

5.1.3. Restraints/challenges

5.1.4. Impact analysis of drivers/restraints

5.2. Impact of COVID-19

5.3. Porter’s Five Forces Analysis

5.3.1. Bargaining power of buyers

5.3.2. Bargaining power of suppliers

5.3.3. Threat of new entrants

5.3.4. Intensity of rivalry

5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview

6.2. Market Volume, by Phase (2017–2030)

6.3. Market Revenue, by Phase (2017–2030)

6.4. Market Volume, by Therapeutic Application (2017–2030)

6.5. Market Revenue, by Therapeutic Application (2017–2030)

6.6. Market Volume, by Service (2017–2030)

6.7. Market Revenue, by Service (2017–2030)

6.8. Market Volume, by End User (2017–2030)

6.9. Market Revenue, by End User (2017–2030)

6.10. Market Volume, by Region (2017–2030)

6.11. Market Revenue, by Region (2017–2030)

Chapter 7. North America Market

7.1. Overview

7.2. Market Volume, by Phase (2017–2030)

7.3. Market Revenue, by Phase (2017–2030)

7.4. Market Volume, by Therapeutic Application (2017–2030)

7.5. Market Revenue, by Therapeutic Application (2017–2030)

7.6. Market Volume, by Service (2017–2030)

7.7. Market Revenue, by Service (2017–2030)

7.8. Market Volume, by End User (2017–2030)

7.9. Market Revenue, by End User (2017–2030)

7.10. Market Volume, by Country (2017–2030)

7.11. Market Revenue, by Country (2017–2030)

Chapter 8. Europe Market

8.1. Overview

8.2. Market Volume, by Phase (2017–2030)

8.3. Market Revenue, by Phase (2017–2030)

8.4. Market Volume, by Therapeutic Application (2017–2030)

8.5. Market Revenue, by Therapeutic Application (2017–2030)

8.6. Market Volume, by Service (2017–2030)

8.7. Market Revenue, by Service (2017–2030)

8.8. Market Volume, by End User (2017–2030)

8.9. Market Revenue, by End User (2017–2030)

8.10. Market Volume, by Country (2017–2030)

8.11. Market Revenue, by Country (2017–2030)

Chapter 9. APAC Market

9.1. Overview

9.2. Market Volume, by Phase (2017–2030)

9.3. Market Revenue, by Phase (2017–2030)

9.4. Market Volume, by Therapeutic Application (2017–2030)

9.5. Market Revenue, by Therapeutic Application (2017–2030)

9.6. Market Volume, by Service (2017–2030)

9.7. Market Revenue, by Service (2017–2030)

9.8. Market Volume, by End User (2017–2030)

9.9. Market Revenue, by End User (2017–2030)

9.10. Market Volume, by Country (2017–2030)

9.11. Market Revenue, by Country (2017–2030)

Chapter 10. LATAM Market

10.1. Overview

10.2. Market Volume, by Phase (2017–2030)

10.3. Market Revenue, by Phase (2017–2030)

10.4. Market Volume, by Therapeutic Application (2017–2030)

10.5. Market Revenue, by Therapeutic Application (2017–2030)

10.6. Market Volume, by Service (2017–2030)

10.7. Market Revenue, by Service (2017–2030)

10.8. Market Volume, by End User (2017–2030)

10.9. Market Revenue, by End User (2017–2030)

10.10. Market Volume, by Country (2017–2030)

10.11. Market Revenue, by Country (2017–2030)

Chapter 11. MEA Market

11.1. Overview

11.2. Market Volume, by Phase (2017–2030)

11.3. Market Revenue, by Phase (2017–2030)

11.4. Market Volume, by Therapeutic Application (2017–2030)

11.5. Market Revenue, by Therapeutic Application (2017–2030)

11.6. Market Volume, by Service (2017–2030)

11.7. Market Revenue, by Service (2017–2030)

11.8. Market Volume, by End User (2017–2030)

11.9. Market Revenue, by End User (2017–2030)

11.10. Market Volume, by Country (2017–2030)

11.11. Market Revenue, by Country (2017–2030)

Chapter 12. U.S. Market

12.1. Overview

12.2. Market Volume, by Phase (2017–2030)

12.3. Market Revenue, by Phase (2017–2030)

12.4. Market Volume, by Therapeutic Application (2017–2030)

12.5. Market Revenue, by Therapeutic Application (2017–2030)

12.6. Market Volume, by Service (2017–2030)

12.7. Market Revenue, by Service (2017–2030)

12.8. Market Volume, by End User (2017–2030)

12.9. Market Revenue, by End User (2017–2030)

Chapter 13. Canada Market

13.1. Overview

13.2. Market Volume, by Phase (2017–2030)

13.3. Market Revenue, by Phase (2017–2030)

13.4. Market Volume, by Therapeutic Application (2017–2030)

13.5. Market Revenue, by Therapeutic Application (2017–2030)

13.6. Market Volume, by Service (2017–2030)

13.7. Market Revenue, by Service (2017–2030)

13.8. Market Volume, by End User (2017–2030)

13.9. Market Revenue, by End User (2017–2030)

Chapter 14. Germany Market

14.1. Overview

14.2. Market Volume, by Phase (2017–2030)

14.3. Market Revenue, by Phase (2017–2030)

14.4. Market Volume, by Therapeutic Application (2017–2030)

14.5. Market Revenue, by Therapeutic Application (2017–2030)

14.6. Market Volume, by Service (2017–2030)

14.7. Market Revenue, by Service (2017–2030)

14.8. Market Volume, by End User (2017–2030)

14.9. Market Revenue, by End User (2017–2030)

Chapter 15. France Market

15.1. Overview

15.2. Market Volume, by Phase (2017–2030)

15.3. Market Revenue, by Phase (2017–2030)

15.4. Market Volume, by Therapeutic Application (2017–2030)

15.5. Market Revenue, by Therapeutic Application (2017–2030)

15.6. Market Volume, by Service (2017–2030)

15.7. Market Revenue, by Service (2017–2030)

15.8. Market Volume, by End User (2017–2030)

15.9. Market Revenue, by End User (2017–2030)

Chapter 16. U.K. Market

16.1. Overview

16.2. Market Volume, by Phase (2017–2030)

16.3. Market Revenue, by Phase (2017–2030)

16.4. Market Volume, by Therapeutic Application (2017–2030)

16.5. Market Revenue, by Therapeutic Application (2017–2030)

16.6. Market Volume, by Service (2017–2030)

16.7. Market Revenue, by Service (2017–2030)

16.8. Market Volume, by End User (2017–2030)

16.9. Market Revenue, by End User (2017–2030)

Chapter 17. Italy Market

17.1. Overview

17.2. Market Volume, by Phase (2017–2030)

17.3. Market Revenue, by Phase (2017–2030)

17.4. Market Volume, by Therapeutic Application (2017–2030)

17.5. Market Revenue, by Therapeutic Application (2017–2030)

17.6. Market Volume, by Service (2017–2030)

17.7. Market Revenue, by Service (2017–2030)

17.8. Market Volume, by End User (2017–2030)

17.9. Market Revenue, by End User (2017–2030)

Chapter 18. Spain Market

18.1. Overview

18.2. Market Volume, by Phase (2017–2030)

18.3. Market Revenue, by Phase (2017–2030)

18.4. Market Volume, by Therapeutic Application (2017–2030)

18.5. Market Revenue, by Therapeutic Application (2017–2030)

18.6. Market Volume, by Service (2017–2030)

18.7. Market Revenue, by Service (2017–2030)

18.8. Market Volume, by End User (2017–2030)

18.9. Market Revenue, by End User (2017–2030)

Chapter 19. Japan Market

19.1. Overview

19.2. Market Volume, by Phase (2017–2030)

19.3. Market Revenue, by Phase (2017–2030)

19.4. Market Volume, by Therapeutic Application (2017–2030)

19.5. Market Revenue, by Therapeutic Application (2017–2030)

19.6. Market Volume, by Service (2017–2030)

19.7. Market Revenue, by Service (2017–2030)

19.8. Market Volume, by End User (2017–2030)

19.9. Market Revenue, by End User (2017–2030)

Chapter 20. China Market

20.1. Overview

20.2. Market Volume, by Phase (2017–2030)

20.3. Market Revenue, by Phase (2017–2030)

20.4. Market Volume, by Therapeutic Application (2017–2030)

20.5. Market Revenue, by Therapeutic Application (2017–2030)

20.6. Market Volume, by Service (2017–2030)

20.7. Market Revenue, by Service (2017–2030)

20.8. Market Volume, by End User (2017–2030)

20.9. Market Revenue, by End User (2017–2030)

Chapter 21. India Market

21.1. Overview

21.2. Market Volume, by Phase (2017–2030)

21.3. Market Revenue, by Phase (2017–2030)

21.4. Market Volume, by Therapeutic Application (2017–2030)

21.5. Market Revenue, by Therapeutic Application (2017–2030)

21.6. Market Volume, by Service (2017–2030)

21.7. Market Revenue, by Service (2017–2030)

21.8. Market Volume, by End User (2017–2030)

21.9. Market Revenue, by End User (2017–2030)

Chapter 22. Australia Market

22.1. Overview

22.2. Market Volume, by Phase (2017–2030)

22.3. Market Revenue, by Phase (2017–2030)

22.4. Market Volume, by Therapeutic Application (2017–2030)

22.5. Market Revenue, by Therapeutic Application (2017–2030)

22.6. Market Volume, by Service (2017–2030)

22.7. Market Revenue, by Service (2017–2030)

22.8. Market Volume, by End User (2017–2030)

22.9. Market Revenue, by End User (2017–2030)

Chapter 23. South Korea Market

23.1. Overview

23.2. Market Volume, by Phase (2017–2030)

23.3. Market Revenue, by Phase (2017–2030)

23.4. Market Volume, by Therapeutic Application (2017–2030)

23.5. Market Revenue, by Therapeutic Application (2017–2030)

23.6. Market Volume, by Service (2017–2030)

23.7. Market Revenue, by Service (2017–2030)

23.8. Market Volume, by End User (2017–2030)

23.9. Market Revenue, by End User (2017–2030)

Chapter 24. Brazil Market

24.1. Overview

24.2. Market Volume, by Phase (2017–2030)

24.3. Market Revenue, by Phase (2017–2030)

24.4. Market Volume, by Therapeutic Application (2017–2030)

24.5. Market Revenue, by Therapeutic Application (2017–2030)

24.6. Market Volume, by Service (2017–2030)

24.7. Market Revenue, by Service (2017–2030)

24.8. Market Volume, by End User (2017–2030)

24.9. Market Revenue, by End User (2017–2030)

Chapter 25. Mexico Market

25.1. Overview

25.2. Market Volume, by Phase (2017–2030)

25.3. Market Revenue, by Phase (2017–2030)

25.4. Market Volume, by Therapeutic Application (2017–2030)

25.5. Market Revenue, by Therapeutic Application (2017–2030)

25.6. Market Volume, by Service (2017–2030)

25.7. Market Revenue, by Service (2017–2030)

25.8. Market Volume, by End User (2017–2030)

25.9. Market Revenue, by End User (2017–2030)

Chapter 26. Saudi Arabia Market

26.1. Overview

26.2. Market Volume, by Phase (2017–2030)

26.3. Market Revenue, by Phase (2017–2030)

26.4. Market Volume, by Therapeutic Application (2017–2030)

26.5. Market Revenue, by Therapeutic Application (2017–2030)

26.6. Market Volume, by Service (2017–2030)

26.7. Market Revenue, by Service (2017–2030)

26.8. Market Volume, by End User (2017–2030)

26.9. Market Revenue, by End User (2017–2030)

Chapter 27. South Africa Market

27.1. Overview

27.2. Market Volume, by Phase (2017–2030)

27.3. Market Revenue, by Phase (2017–2030)

27.4. Market Volume, by Therapeutic Application (2017–2030)

27.5. Market Revenue, by Therapeutic Application (2017–2030)

27.6. Market Volume, by Service (2017–2030)

27.7. Market Revenue, by Service (2017–2030)

27.8. Market Volume, by End User (2017–2030)

27.9. Market Revenue, by End User (2017–2030)

Chapter 28. U.A.E. Market

28.1. Overview

28.2. Market Volume, by Phase (2017–2030)

28.3. Market Revenue, by Phase (2017–2030)

28.4. Market Volume, by Therapeutic Application (2017–2030)

28.5. Market Revenue, by Therapeutic Application (2017–2030)

28.6. Market Volume, by Service (2017–2030)

28.7. Market Revenue, by Service (2017–2030)

28.8. Market Volume, by End User (2017–2030)

28.9. Market Revenue, by End User (2017–2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings

29.2. Competitive Benchmarking of Key Players

29.3. Product Benchmarking of Key Players

29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. Thermo Fisher Scientific Inc.

30.1.1. Business overview

30.1.2. Product and service offerings

30.1.3. Key financial summary

30.2. Marken

30.2.1. Business overview

30.2.2. Product and service offerings

30.2.3. Key financial summary

30.3. Catalent Inc.

30.3.1. Business overview

30.3.2. Product and service offerings

30.3.3. Key financial summary

30.4. Parexel International

30.4.1. Business overview

30.4.2. Product and service offerings

30.4.3. Key financial summary

30.5. Almac Group Limited

30.5.1. Business overview

30.5.2. Product and service offerings

30.5.3. Key financial summary

30.6. Biocair International Limited

30.6.1. Business overview

30.6.2. Product and service offerings

30.6.3. Key financial summary

30.7. Sharp Services LLC

30.7.1. Business overview

30.7.2. Product and service offerings

30.7.3. Key financial summary

30.8. Movianto International BV

30.8.1. Business overview

30.8.2. Product and service offerings

30.8.3. Key financial summary

30.9. PCI Pharma Services

30.9.1. Business overview

30.9.2. Product and service offerings

30.9.3. Key financial summary

30.10. Eurofins Scientific

30.10.1. Business overview

30.10.2. Product and service offerings

30.10.3. Key financial summary

Chapter 31. Appendix

31.1. Abbreviations

31.2. Sources and References

31.3. Related Reports

※参考情報 臨床試験用品とは、医薬品や医療機器の臨床試験に使用されるアイテムや装置のことを指します。これらの用品は、治療法や治療薬の安全性および有効性を評価するための重要な役割を果たしています。臨床試験は、新しい治療法や薬剤が患者にどのような影響を及ぼすかを理解するために必要不可欠なプロセスであり、これをサポートするさまざまな用品が存在します。 臨床試験用品の種類は多岐にわたります。まず、最も基本的なものとして、医薬品そのものが挙げられます。これは、新しい薬剤の有効性を評価するために使用されるもので、錠剤、注射液、点滴などの形態を取ります。これらは被験者に投与され、治療効果や副作用が観察されます。 次に、医療機器も重要な臨床試験用品です。これには、診断機器や治療機器が含まれます。例えば、MRIやCTスキャンなどの画像診断装置、血圧計、心電図などが該当します。これらの器具は、患者の状態を正確に把握し、治療への反応を測定するために使用されます。 さらに、臨床試験においては、生物試料も重要な役割を果たします。血液や尿、組織サンプルなどが採取されて、分析が行われることで、薬剤の効果や副作用についての情報が得られます。これにより、研究者は薬剤の作用メカニズムやその安全性を把握することが可能になります。 また、データ収集用のツールも臨床試験用品の一部です。これには、電子カルテやデータ管理システム、アンケート調査用のツールが含まれます。これらは試験の進行状況や患者の反応を記録し、分析するために不可欠です。特に最近では、電子化が進歩し、リアルタイムでデータを収集・分析することができるシステムが広く使用されています。 臨床試験用品の用途は、主に新薬や新しい治療法の開発に関連しています。新薬を開発する過程では、複数のフェーズに分かれた臨床試験を実施し、各フェーズで安全性や有効性を評価します。これにより、最終的には承認された薬剤が市場に出ることを目指します。臨床試験は、製薬会社や医療機関、研究機関などが協力して行うものであり、倫理的な配慮が常に求められます。 臨床試験用品に関連する技術も非常に重要です。バイオテクノロジーや遺伝子工学の進展により、個別化医療が進んでいます。これにより、患者一人ひとりの遺伝的背景に基づいた治療法が開発され、より効果的な治療が期待できます。また、デジタル技術の進化により、患者の健康状態を遠隔でモニタリングすることが可能になり、臨床試験の効率が向上しています。 さらに、臨床試験の運営においては、倫理委員会の承認を得ることが必須です。これは、被験者が安全に試験に参加できるよう、倫理的な基準を遵守するためです。また、参加者に対して十分なインフォームドコンセントが求められます。これは、試験の目的やリスク、利益について十分に説明し、被験者が理解した上で参加することに同意するプロセスです。 最後に、臨床試験用品は、医療の発展に寄与するだけでなく、患者に新たな治療の選択肢を提供するものでもあります。新薬や新しい治療法の開発が進むことで、より多くの病気への対策が可能になり、患者の生活の質が向上します。臨床試験が適切に行われることで、医療の未来がより明るいものとなることが期待されます。これにより、患者にとっても医療技術の進歩が身近に感じられるようになるのです。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer